Canada - English - Health Canada

taro pharmaceuticals inc - docetaxel - solution - 80mg - docetaxel 80mg - antineoplastic agents

Canada - English - Health Canada

taro pharmaceuticals inc - docetaxel - solution - 160mg - docetaxel 160mg - antineoplastic agents

Canada - English - Health Canada

pharmascience inc - docetaxel - solution - 20mg - docetaxel 20mg - antineoplastic agents

Canada - English - Health Canada

pharmascience inc - docetaxel - solution - 80mg - docetaxel 80mg - antineoplastic agents

United States - English - NLM (National Library of Medicine)

armas pharmaceuticals inc. - docetaxel (unii: 15h5577cqd) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

United States - English - NLM (National Library of Medicine)

armas pharmaceuticals inc. - docetaxel (unii: 15h5577cqd) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

United States - English - NLM (National Library of Medicine)

armas pharmaceuticals inc. - docetaxel (unii: 15h5577cqd) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

United States - English - NLM (National Library of Medicine)

mylan institutional llc - docetaxel (unii: 15h5577cqd) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced gastric adenocarcinoma, including adenocarcinoma of the gastroesophageal junction, who have not received prior chemotherapy for advanced disease. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck (scchn). docetaxel injection is contraindicated in patients with: based on findings in animal reproduction studies and its mechanism of action, docetaxel injection can cause fetal harm when administered to a pregnant woman [see clinical pharmacology (12.1)] . available data from case reports in the literature and pharmacovigilance with docetaxel use in pregnant women are not sufficient to inform the drug-associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcomes. docetaxel injection contains alcohol which can interfere with neurobehavioral development (see clinical considerations ). in animal reproductive studies, administration of docetaxel to pregnant rats and rabbits during the period of organogenesis caused an increased incidence of embryo-fetal toxicities, including intrauterine mortality, at doses as low as 0.02 and 0.003 times the recommended human dose based on body surface area, respectively (see data ). advise pregnant women and females of reproductive potential of the potential risk to a fetus. the estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. all pregnancies have a background risk of birth defect, miscarriage, or other adverse outcomes. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively. docetaxel injection contains alcohol [see warnings and precautions (5.13)] . published studies have demonstrated that alcohol is associated with fetal harm including central nervous system abnormalities, behavioral disorders, and impaired intellectual development. intravenous administration of ≥0.3 and 0.03 mg/kg/day docetaxel to pregnant rats and rabbits, respectively, during the period of organogenesis caused an increased incidence of intrauterine mortality, resorptions, reduced fetal weights, and fetal ossification delays. maternal toxicity was also observed at these doses, which were approximately 0.02 and 0.003 times the daily maximum recommended human dose based on body surface area, respectively. there is no information regarding the presence of docetaxel in human milk, or on its effects on milk production or the breastfed child. no lactation studies in animals have been conducted. because of the potential for serious adverse reactions in a breastfed child, advise women not to breastfeed during treatment with docetaxel injection and for 1 week after the last dose. based on findings in animals, docetaxel injection can cause fetal harm when administered to a pregnant woman [see use in specific populations (8.1)] . verify pregnancy status in females of reproductive potential prior to initiating docetaxel injection. based on genetic toxicity findings, advice females of reproductive potential to use effective contraception during treatment and for 2 months after the last dose of docetaxel injection. based on genetic toxicity findings, advise male patients with female partners of reproductive potential to use effective contraception during treatment and for 4 months after the last dose of docetaxel injection. based on findings in animal studies, docetaxel injection may impair fertility in males of reproductive potential [see nonclinical toxicology (13.1)] . the alcohol content of docetaxel injection should be taken into account when given to pediatric patients [see warnings and precautions (5.13)] . the efficacy of docetaxel in pediatric patients as monotherapy or in combination has not been established. the overall safety profile of docetaxel in pediatric patients receiving monotherapy or tcf was consistent with the known safety profile in adults. docetaxel has been studied in a total of 289 pediatric patients: 239 in 2 trials with monotherapy and 50 in combination treatment with cisplatin and 5-fluorouracil (tcf). docetaxel monotherapy was evaluated in a dose-finding phase 1 trial in 61 pediatric patients (median age 12.5 years, range 1 to 22 years) with a variety of refractory solid tumors. the recommended dose was 125 mg/m2 as a 1-hour intravenous infusion every 21 days. the primary dose limiting toxicity was neutropenia. the recommended dose for docetaxel monotherapy was evaluated in a phase 2 single-arm trial in 178 pediatric patients (median age 12 years, range 1 to 26 years) with a variety of recurrent/refractory solid tumors. efficacy was not established with tumor response rates ranging from one complete response (cr) (0.6%) in a patient with undifferentiated sarcoma to four partial responses (2.2%) seen in one patient each with ewing sarcoma, neuroblastoma, osteosarcoma, and squamous cell carcinoma. docetaxel was studied in combination with cisplatin and 5-fluorouracil (tcf) versus cisplatin and 5-fluorouracil (cf) for the induction treatment of nasopharyngeal carcinoma (npc) in pediatric patients prior to chemoradiation consolidation. seventy-five patients (median age 16 years, range 9 to 21 years) were randomized (2:1) to docetaxel (75 mg/m2 ) in combination with cisplatin (75 mg/m2 ) and 5-fluorouracil (750 mg/m2 ) (tcf) or to cisplatin (80 mg/m2 ) and 5-fluorouracil (1000 mg/m2 /day) (cf). the primary endpoint was the cr rate following induction treatment of npc. one patient out of 50 in the tcf group (2%) had a complete response while none of the 25 patients in the cf group had a complete response. pharmacokinetic parameters for docetaxel were determined in 2 pediatric solid tumor trials. following docetaxel administration at 55 mg/m2 to 235 mg/m2 in a 1-hour intravenous infusion every 3 weeks in 25 patients aged 1 to 20 years (median 11 years), docetaxel clearance was 17.3±10.9 l/h/m2 . docetaxel was administered in combination with cisplatin and 5-fluorouracil (tcf), at dose levels of 75 mg/m2 in a 1-hour intravenous infusion day 1 in 28 patients aged 10 to 21 years (median 16 years, 17 patients were older than 16). docetaxel clearance was 17.9±8.75 l/h/m2 , corresponding to an auc of 4.20±2.57 mcg•h/ml. in summary, the body surface area adjusted clearance of docetaxel monotherapy and tcf combination in children were comparable to those in adults [see clinical pharmacology (12.3)] . in general, dose selection for an elderly patient should be cautious, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy in elderly patients. in a study conducted in chemotherapy-naïve patients with nsclc (tax326), 148 patients (36%) in the docetaxel+cisplatin group were 65 years of age or greater. there were 128 patients (32%) in the vinorelbine+cisplatin group 65 years of age or greater. in the docetaxel+cisplatin group, patients less than 65 years of age had a median survival of 10.3 months (95% ci: 9.1 months, 11.8 months) and patients 65 years or older had a median survival of 12.1 months (95% ci: 9.3 months, 14 months). in patients 65 years of age or greater treated with docetaxel+cisplatin, diarrhea (55%), peripheral edema (39%) and stomatitis (28%) were observed more frequently than in the vinorelbine+cisplatin group (diarrhea 24%, peripheral edema 20%, stomatitis 20%). patients treated with docetaxel+cisplatin who were 65 years of age or greater were more likely to experience diarrhea (55%), infections (42%), peripheral edema (39%) and stomatitis (28%) compared to patients less than the age of 65 administered the same treatment (43%, 31%, 31% and 21%, respectively). when docetaxel was combined with carboplatin for the treatment of chemotherapy-naïve, advanced non-small cell lung carcinoma, patients 65 years of age or greater (28%) experienced higher frequency of infection compared to similar patients treated with docetaxel+cisplatin, and a higher frequency of diarrhea, infection and peripheral edema than elderly patients treated with vinorelbine+cisplatin. of the 333 patients treated with docetaxel every three weeks plus prednisone in the prostate cancer study (tax327), 209 patients were 65 years of age or greater and 68 patients were older than 75 years. in patients treated with docetaxel every three weeks, the following treatment-emergent adverse reactions occurred at rates ≥10% higher in patients 65 years of age or greater compared to younger patients: anemia (71% vs. 59%), infection (37% vs. 24%), nail changes (34% vs. 23%), anorexia (21% vs. 10%), weight loss (15% vs. 5%), respectively. in the adjuvant breast cancer trial (tax316), docetaxel in combination with doxorubicin and cyclophosphamide was administered to 744 patients of whom 48 (6%) were 65 years of age or greater. the number of elderly patients who received this regimen was not sufficient to determine whether there were differences in safety and efficacy between elderly and younger patients. among the 221 patients treated with docetaxel injection in combination with cisplatin and fluorouracil in the gastric cancer study, 54 were 65 years of age or older and 2 patients were older than 75 years. in this study, the number of patients who were 65 years of age or older was insufficient to determine whether they respond differently from younger patients. however, the incidence of serious adverse reactions was higher in the elderly patients compared to younger patients. the incidence of the following adverse reactions (all grades, regardless of relationship): lethargy, stomatitis, diarrhea, dizziness, edema, febrile neutropenia/neutropenic infection occurred at rates ≥10% higher in patients who were 65 years of age or older compared to younger patients. elderly patients treated with tcf should be closely monitored. among the 174 and 251 patients who received the induction treatment with docetaxel injection in combination with cisplatin and fluorouracil (tpf) for scchn in the tax323 and tax324 studies, 18 (10%) and 32 (13%) of the patients were 65 years of age or older, respectively. these clinical studies of docetaxel injection in combination with cisplatin and fluorouracil in patients with scchn did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. other reported clinical experience with this treatment regimen has not identified differences in responses between elderly and younger patients. avoid docetaxel injection in patients with bilirubin > uln and patients with ast and/or alt >1.5 × uln concomitant with alkaline phosphatase >2.5 × uln [see boxed warning, warnings and precautions (5.2), clinical pharmacology (12.3)] . the alcohol content of docetaxel injection should be taken into account when given to patients with hepatic impairment [see warnings and precautions (5.13)] .

United States - English - NLM (National Library of Medicine)

northstar rxllc - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel anhydrous 20 mg in 1 ml

European Union - English - EMA (European Medicines Agency)

mylan s.a.s. - docetaxel - head and neck neoplasms; carcinoma, non-small-cell lung; adenocarcinoma; prostatic neoplasms; breast neoplasms - antineoplastic agents - treatment of breast cancer, special forms of lung cancer (non-small-cell lung cancer), prostate cancer, gastric cancer, or head and neck cancer.